Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00115024 | EPAT: Estrogen in the Prevention of Atherosclerosis Trial | PHASE2 | COMPLETED | 222 | — | — | Apr 1, 1994 | Nov 1, 1998 | Dec 11, 2009 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Micronized 17B-estradiol | DRUG | - |
Inclusion Criteria: * Postmenopausal female (serum estradiol less than 20 pg/ml) * 46 to 80 years old * Fasting LDL-C levels 130 to 210 mg/dL * Triglyceride levels less than 400 mg/dL * Current non-smoker Exclusion Criteria: * Clinical evidence of cardiovascular disease * HDL-C level less than 30...